Barclays Forecasts Strong Price Appreciation for Colgate-Palmolive (NYSE:CL) Stock

Colgate-Palmolive (NYSE:CL) had its target price upped by equities research analysts at Barclays from $87.00 to $95.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price target indicates a potential downside of 2.65% from the company’s previous close.

Other research analysts also recently issued reports about the company. TD Cowen boosted their target price on Colgate-Palmolive from $90.00 to $97.00 and gave the stock a “hold” rating in a report on Monday. Jefferies Financial Group reiterated a “hold” rating and issued a $89.00 price objective (up from $88.00) on shares of Colgate-Palmolive in a research report on Monday, August 3rd. Royal Bank Of Canada boosted their price objective on Colgate-Palmolive from $104.00 to $105.00 and gave the stock an “outperform” rating in a research note on Monday. Evercore lifted their price target on Colgate-Palmolive from $100.00 to $101.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Finally, Bank of America upped their price target on shares of Colgate-Palmolive from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday. Thirteen research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Colgate-Palmolive currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.22.

Colgate-Palmolive Trading Up 2.4%

Shares of CL stock opened at $97.59 on Tuesday. The company has a market capitalization of $77.79 billion, a P/E ratio of 38.27, a P/E/G ratio of 4.44 and a beta of 0.31. Colgate-Palmolive has a 12-month low of $74.54 and a 12-month high of $99.33. The company has a quick ratio of 0.67, a current ratio of 1.03 and a debt-to-equity ratio of 13.82. The firm has a 50-day moving average price of $89.67 and a 200 day moving average price of $89.72.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, October 30th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.34 billion. Colgate-Palmolive had a net margin of 9.68% and a return on equity of 464.63%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.91 earnings per share. Research analysts forecast that Colgate-Palmolive will post 3.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Panagiotis Tsourapas sold 10,000 shares of the business’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $92.05, for a total transaction of $920,500.00. Following the completion of the sale, the chief operating officer owned 64,901 shares in the company, valued at $5,974,137.05. The trade was a 13.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director John Cahill sold 4,170 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $93.37, for a total value of $389,352.90. Following the completion of the transaction, the director owned 28,373 shares in the company, valued at approximately $2,649,187.01. This represents a 12.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.43% of the company’s stock.

Hedge Funds Weigh In On Colgate-Palmolive

Large investors have recently bought and sold shares of the business. United Advisor Group LLC increased its holdings in Colgate-Palmolive by 16.4% in the third quarter. United Advisor Group LLC now owns 3,397 shares of the company’s stock valued at $290,000 after purchasing an additional 478 shares during the last quarter. Plancorp LLC grew its position in shares of Colgate-Palmolive by 7.3% during the 3rd quarter. Plancorp LLC now owns 7,088 shares of the company’s stock worth $605,000 after buying an additional 481 shares during the period. Ashton Thomas Private Wealth LLC grew its position in shares of Colgate-Palmolive by 2.2% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 11,580 shares of the company’s stock worth $988,000 after buying an additional 248 shares during the period. Calamos Wealth Management LLC increased its stake in shares of Colgate-Palmolive by 9.8% in the 3rd quarter. Calamos Wealth Management LLC now owns 14,575 shares of the company’s stock valued at $1,244,000 after acquiring an additional 1,298 shares during the last quarter. Finally, Alta Advisers Ltd increased its stake in shares of Colgate-Palmolive by 101.9% in the 3rd quarter. Alta Advisers Ltd now owns 5,390 shares of the company’s stock valued at $460,000 after acquiring an additional 2,720 shares during the last quarter. 80.41% of the stock is currently owned by institutional investors and hedge funds.

Key Colgate-Palmolive News

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Improved quarterly performance and guidance: Colgate-Palmolive reported 4.6% year-over-year sales growth, exceeded third-quarter earnings and revenue expectations, and raised its margin and EPS outlook. The company also narrowed its 2026 sales guidance, signaling continued operating resilience. Colgate-Palmolive sales rise 4.6% and it lifts margin and EPS outlook
• Positive Sentiment: Demand and innovation remain constructive: Management highlighted steady global demand and premium product innovation as growth drivers, helping offset inflation and other cost pressures. CL Q3 deep dive: global demand and premium innovation support steady growth amid cost pressures
• Positive Sentiment: Analyst targets moved higher: Morgan Stanley raised its target to $111 and kept an overweight rating; BNP Paribas Exane increased its target to $108 while maintaining outperform; and RBC raised its target to $105 with an outperform rating. These revisions reflect greater confidence following the earnings report. Colgate-Palmolive Analysts Boost Their Forecasts After Upbeat Q3 Earnings
• Neutral Sentiment: Analyst opinion is not unanimous: JPMorgan trimmed its price target to $102 but retained an overweight rating, while Wells Fargo raised its target to $95 but maintained equal weight. Barclays also reiterated a hold rating, suggesting some analysts believe much of the positive earnings news is already reflected in the valuation. Barclays Sticks to Its Hold Rating for Colgate-Palmolive
• Negative Sentiment: Valuation and profitability concerns remain: Commentary notes that CL trades at a substantially higher forward earnings multiple than Lululemon, raising questions about whether its defensive growth profile justifies the premium. Investors are also monitoring cost inflation and lingering questions about profit growth. Lululemon trades at half the forward P/E of Colgate-Palmolive

About Colgate-Palmolive

Colgate-Palmolive Company (NYSE: CL) is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwash, liquid hand soap, body wash, deodorants, household cleaning products and pet food and treats.

The company markets well-known brands such as Colgate, Palmolive, elmex, meridol, Softsoap, Irish Spring, Ajax, Protex and Hill’s Science Diet. Colgate-Palmolive also provides veterinary and nutritional products through Hill’s Pet Nutrition, which serves pet owners and animal health professionals.

Founded in 1806 by William Colgate, the company developed from a soap and candle business into a diversified consumer goods manufacturer.